Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 5/20 | 0.34 |
| ▸ | CTSL | P07711 | 3/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | GHSR | Q92847 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8895999 | 0.83 | PBRM1 (0.35) | LMNAPBRM1CTSSCTSLCYP3A4 | |
| Phenoxyethanol SCHEMBL5691829 | 0.81 | ALDH1A1 (0.51) | LMNACYP3A4TDP1 | |
| SCHEMBL8895995 | 0.80 | PBRM1 (0.33) | LMNAPBRM1CTSSCTSLCYP3A4 | |
| SCHEMBL7764504 | 0.77 | LMNA (0.43) | LMNAMTNR1AMTNR1BCYP2D6GHSR | |
| Water SCHEMBL30489926 | 0.76 | LMNA (0.50) | LMNAMTNR1AMTNR1BCYP2D6 | |
| Water SCHEMBL28244606 | 0.76 | LMNA (0.50) | LMNAMTNR1AMTNR1BCYP2D6 | |
| SCHEMBL223764 | 0.76 | TSHR (0.32) | — | |
| SCHEMBL5484514 | 0.74 | TSHR (0.31) | — | |
| SCHEMBL167127 | 0.74 | LMNA (0.52) | LMNAMTNR1AMTNR1BCYP2D6 | |
| SCHEMBL15709 | 0.74 | LMNA (0.52) | LMNAMTNR1AMTNR1BCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699219-B1 | SELF-TANNING COMPOSITIONS HAVING REDUCED MAILLARD REACTION MALODOR | KAO USA INC (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20170290758-A1 | Optimized Skincare Regimens for Changing the Genetic Skin Type to the Ideal Skin Type - Oily, Resistant, Non-Pigmented and Tight Skin | METABEAUTY, INC. | 2017-10-12 | — | — | US | disclosed |
| US-9724287-B2 | Optimized skincare regimens for changing the genetic skin type to the ideal skin type—oily, resistant, non-pigmented and tight skin | METABEAUTY, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9452125-B2 | Self-tanning compositions having reduced maillard reaction malodor | KAO USA INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160128925-A1 | Optimized Skincare Regimens for Changing the Genetic Skin Type to the Ideal Skin Type - Oily, Resistant, Non-Pigmented and Tight Skin | METABEAUTY, INC. | 2016-05-12 | — | — | US | disclosed |
| EP-2699219-A2 | SELF-TANNING COMPOSITIONS HAVING REDUCED MAILLARD REACTION MALODOR | Kao Corporation (JP) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012145638-A2 | SELF-TANNING COMPOSITIONS HAVING REDUCED MAILLARD REACTION MALODOR | KAO CORPORATION (JP) | 2012-10-26 | — | — | WO | disclosed |
| US-20120269743-A1 | SELF-TANNING COMPOSITIONS HAVING REDUCED MAILLARD REACTION MALODOR | KAO USA INC. (US) | 2012-10-25 | — | — | US | disclosed |
| EP-0907355-A1 | SKIN WASH COMPOSITIONS COMPRISING TRICLOCARBAN AND SURFACTANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997048377-A1 | SKIN WASH COMPOSITIONS COMPRISING TRICLOCARBAN AND SURFACTANTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160128925-A1 | Optimized Skincare Regimens for Changing the Genetic Skin Type to the Ideal Skin Type - Oily, Resistant, Non-Pigmented and Tight Skin | CUTA, UBQLN2, BRCA1 | LMNA 643/4885PBRM1 2149/4885CTSS 4804/4885 |
| US-20170290758-A1 | Optimized Skincare Regimens for Changing the Genetic Skin Type to the Ideal Skin Type - Oily, Resistant, Non-Pigmented and Tight Skin | CUTA, UBQLN2, BRCA1 | LMNA 643/4885PBRM1 2149/4885CTSS 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.